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PS224.
Nogo-B Protein Modulates Intimal Thickening Dur-
ing Vein Graft Adaptation
Yuka Kondo, Akihito Muto, Tai Yi, Amanda Feigel, Ken-
neth Ziegler, Lynn Model, Sammy Eghbalieh, Jun Yu,
William Sessa, Alan Dardik. Yale University, New Haven,
CT
Objectives: Nogo-B is a protective factor in the vascu-
lar system, limiting the response to arterial injury. We
hypothesized that Nogo-B would diminish in thickened
vein grafts after exposure to arterial levels of pressure and
shear stress. We examined the expression of Nogo-B, as
well as its three receptors, Nogo-receptor (NgR), Nogo-B-
receptor (NgBR), and PirB (Paired immunoglobulin-like
receptor B), during mouse vein graft adaptation.
Methods:The intrathoracic inferior vena cava (IVC) of
C57Bl/6 (WT) or Nogo-A/B knockout (Nogo-KO) mice
was harvested and implanted as an interposition vein graft
into WT mice. Vein grafts were harvested and analyzed
after 3 weeks. mRNA transcript levels of Nogo-B, NgR,
NgBR, PirB and GAPDH were measured by qPCR. Im-
munohistology (IHC) and Western blotting were per-
formed using the antibodies: Nogo (N18: Santa Cruz),
Nogo-B (1761), F4/80 (AbD serotec).
Results: All vein grafts showed significant wall thick-
ening, with increased thickening in Nogo-KO compared to
WT grafts (0.125  .025 mm vs 0.043  0.003 mm, n 
4; p 0.05). InWT vein grafts, Nogo-B protein levels were
strongly increased compared to preimplantation IVC (IHC
density 6-fold, Western blot density 10-fold). Nogo-B
RNA transcripts were increased 2-fold in the vein graft
compared to IVC. Transcript levels of the NgR and NgBR
were unchanged in vein grafts compared to IVC, whereas
PirB transcript levels were increased approximately 20-fold
(n  3; p  0.05).
Conclusions: Nogo-B transcripts and protein, as well
as transcripts for its PirB receptor, were increased during
vein graft adaptation, suggesting that graft adaptation is
not a response to injury, but an adaptive remodeling re-
sponse. Nogo-B is a factor limiting this adaptive response,
and may signal via the PirB receptor. These results suggest
that Nogo-B signaling is a mechanism of vein graft adapta-
tion and might be a therapeutic target for human trials
targeting vein graft disease.
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Nitric Oxide Decreases the Expression of the 11S Pro-
teasome Activator In Vivo
Nick D. Tsihlis, Ashley Vavra, Janet Martinez, Bo Fu, Qun
Jiang, Melina R. Kibbe. Vascular Surgery, Northwestern
University, Chicago, IL
Objectives:The 26S proteasome degrades themajority
of proteins in eukaryotic cells. The 11S proteasome activa-
tor (PA28) binds to the proteasome and increases its ability
to degrade small peptides. Expression of the PA28 subunits
(, , ) is induced by interferon- stimulation. Since
inflammation plays a role in the development of neointimal
hyperplasia, and since nitric oxide (NO) reduces neointimal
hyperplasia in animal models, we hypothesize that NO will
reduce the expression of PA28.
Methods: The carotid artery balloon injury model was
performed in 11-week-old male Sprague Dawley rats. Treat-
ment groups included injury or injuryPROLI/NO (20 mg).
PA28 subunit expression was assessed by Western blot
analysis on homogenized arteries excised 3 days after injury
(n  3/group) and by immunofluorescent staining of
carotid artery sections harvested 14 days after injury (n 
3/group). Contralateral arteries served as uninjured con-
trols.
Results: Following arterial injury, Western blot analy-
sis showed that expression of the PA28,  and  subunits
remained unchanged. However, after injury and treatment
with NO, expression of the PA28,  and  subunits
decreased substantially in the carotid artery lysates (1.9-,
2.3- and 3.4-fold, respectively). Immunofluorescence
staining of carotid artery sections following injury revealed
a slight increase in the expression of PA28 in the adven-
titia, perhaps due to multimeric PA28 binding the anti-
body more effectively. The expression of PA28 and 
following injury were relatively similar to control. NO
significantly decreased the expression of PA28 in the
media, whereas NOdecreased the expression of PA28 and
 throughout the neointima, media and adventitia.
Conclusions:We report that NOdecreased the expres-
sion of PA28 ,  and  following arterial injury in vivo.
Since the PA28 subunits are involved in the breakdown of
peptides during inflammation, PA28 inhibition may be one
mechanism by which NO inhibits neointimal hyperplasia.
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Cilostazol Causes Angiogenesis Mediated Through the
Enhancement of Nitric Oxide Production in Athe Isch-
emic Hindlimb of Mouse
Akihiko Hori, Rei Shibata, Hiroshi Narita, Masayoshi Koba-
yashi, Kiyohito Yamamoto, Kimihiro Komori. Nagoya Uni-
versity Graduate School of Medicine, Nagoya, Japan.
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itor of phosphordiesterase 3 (PDE3) and is generally used
as a pharmacological tool in the patients with peripheral
arterial disease (PAD). Cilostazol has several beneficial
effects, however, little information is available about the
angiogenesis. In the present study, we investigated whether
cilostazol induces improvement of blood flow in the isch-
emic hindlimb of mouse, and if so, examined the mecha-
nisms of angiogenesis.
Methods: Wild-type (WT) mice were separated into
two groups. One is control group that was treated regular
food. The other is cilostazol group that was treated cilosta-
zol as food admixture at a concentration of 0.1%. Ischemic
hindlimb model of mice was made by ligation left femoral
artery and branched artery. Laser Doppler measurements of
blood flowwere compared between the control and cilosta-
zol group, on before and postoperative days 0,3,7 and 14.
The effect of NOS inhibitor (NG-nitro-L-arginine methyl
ester) on cilostazol group was also investigated using Laser
Doppler analysis. Capillary density in histological samples
of adductor muscle immunostained with an anti-CD31
monoclonal antibody was observed on postoperative day
14. The phosphorylation of endothelial nitric oxide syn-
thase (eNOS) was assessed by Western blot analysis on
postoperative day 5.Results: In cilostazol group, an angio-
genesis by laser Doppler measurements of blood flow
(p0.05) and capillary density in adductor muscle
(p0.05) in ischemic hindlimb model of mice were signif-
icantly enhanced compared to non-treated mice (control),
respectively. Cilostazol-induced angiogenesis were signifi-
cantly inhibited by treatment of NOS inhibitor. Western
blot analysis demonstrated that treatment with Cilostazol
induced the increasing in eNOS phosphorylation in isch-
emic tissue.
Conclusions: These results suggest that cilostazol
caused angiogenesis in ischemic hindlimb model of mouse.
This angiogenesis may be due to the enhancement of nitric
oxide production.
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A Novel In Vitro Model of Chronic Venous Insuffi-
ciency
Carolyn Glass, John Cullen, Yanji Qi, Elisa Roztocil, Mi-
chael Singh, Karl Illig, David Gillespie. Division of Vascular
Surgery, University of Rochester, Rochester, NY
Objectives: Chronic venous insufficiency (CVI) is an
enormous health burden, affecting 2.5 million patients
with advanced disease and leg ulceration per year with costs
in the United States alone exceeding $1 billion annually.
We developed a novel in-vitro cell culture model to exam-ine alterations in the TGF-1 pathway, previously shown to
be disrupted in human venous ulcers.
Methods: Commercially available healthy, adult der-
mal fibroblasts (early passage) were used to represent “nor-
mal fibroblasts” not yet subjected to the pathologic stretch
experienced in CVI. The healthy fibroblasts were incubated
on collagen coated plates, and a Flexercell® strain unit set
to continuous stretch at 21% above ATM with equibiaxial
elongation was used to subject these cells to a pathologic
stretch environment for 1, 5 and 7 days. Alterations in
TGF-1 secretion and TGF-1 Receptor (I and II) expres-
sion in response to mechanical stretch were detected by
fluorescence activated cell sorting analysis (flow cytometry)
and measured by % antibody expression and mean fluores-
cent intensity. Extracellular (secreted) TGF-1 was quan-
tified in media using enzyme linked immunosorbent assay
and fibroblast migratory capacity was measured using the
Boyden chamber transwell migration assay.
Results: TGF-1 secretion from dermal fibroblasts
subjected to 24 hours of stretch was 5-fold less compared to
their control (1169 vs 219 pg/mL, p  0.05). Transwell
migration was also reduced in stretched cells. A significant
reduction in TGF-1 Receptor I expression (70.4% vs
36.1%, p  0.04) following 5 days of mechanical stretch
was also demonstrated.
Conclusions:This model reliably induces reproducible
TGF-1 dysregulation in dermal fibroblasts. Our results
support the observation that pathological dermal stretch is
associated with and plays an integral role in the disruption
of the TGF-1 pathway present in CVI.
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PS232.
Expression of the Heat Shock Protein HSPB1 Is Asso-
ciated With Impaired Smooth Muscle Relaxation
Syed Z. Rizvi, Kyle M. Hocking, Erica Morley, Padmini
Komalavilas, Joyce Cheung-Flynn, Colleen M. Brophy.
Vascular Surgery, Vanderbilt University Medical Center,
Nashville, TN
Objectives: The small heat shock protein (HSP27 or
HSPB1) has been implicated in regulating vascular smooth
muscle tone. HSPB1 is phosphorylated by a stress activated
signaling cascade which includes p38 MAP kinase and
MAPKAP kinase II (MK2). The purpose of this investiga-
tion was to determine if HSPB1 expression correlated with
vascular responses in human saphenous vein (HSV).
Methods: Discarded segments of HSV after peripheral/
coronary revascularizations were tested in muscle bath.
Immunoblotting was performed to determine HSPB1
expression.
